Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT

被引:48
作者
Lawal, Ismaheel O. [1 ,2 ]
Ankrah, Alfred O. [1 ,2 ,3 ]
Mokgoro, Neo P. [1 ,2 ]
Vorster, Mariza [1 ,2 ]
Maes, Alex [1 ,2 ,4 ]
Sathekge, Mike M. [1 ,2 ]
机构
[1] Univ Pretoria, Dept Nucl Med, Private Bag X169, ZA-0001 Pretoria, South Africa
[2] Steve Biko Acad Hosp, Private Bag X169, ZA-0001 Pretoria, South Africa
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands
[4] AZ Groeninge, Dept Nucl Med, Kortrijk, Belgium
关键词
Tc-99m; PET/CT; prostate cancer; PSMA; SPECT/CT; GA-68-PSMA-HBED-CC PET; CANCER; INHIBITOR; MEDICINE;
D O I
10.1002/pros.23379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Emerging data from published studies are demonstrating the superiority of Ga-68 PSMA PET/CT imaging in prostate cancer. However, the low yield of the Ge68/Ga-68 from which Gallium-68 is obtained and fewer installed PET/CT systems compared to the SPECT imaging systems may limit its availability. We, therefore, evaluated in a head-to-head comparison, the diagnostic sensitivity of Ga-68 PSMA PET/CT and Tc-99m PSMA SPECT/CT in patients with prostate cancer. Methods: A total of 14 patients with histologically confirmed prostate cancer were prospectively recruited to undergo Ga-68 PSMA PET/CT and Tc-99m HYNIC PSMA SPECT/CT. The mean age of patients was 67.21 +/- 8.15 years and the median PSA level was 45.18 ng/mL (range = 1.51-687 ng/mL). SUVmax of all lesions and the size of lymph nodes with PSMA avidity on Ga-68 PSMA PET/CT were determined. Proportions of these lesions detected on Tc-99m HYNIC PSMA SPECT/CT read independent of PET/CT findings were determined. Results: A total of 46 lesions were seen on Ga-68 PSMA PET/CT localized to the prostate (n = 10), lymphnodes (n = 24), and bones (n = 12). Of these, Tc-99m HYNIC PSMA SPECT/CT detected 36 lesions: Prostate = 10/10 (100%), lymph nodes = 15/24 (62.5%), and bones = 11/12 (91.7%) with an overall sensitivity of 78.3%. Lesions detected on Tc-99m HYNIC PSMA SPECT/CT were bigger in size (P < 0.001) and had higher SUVmax (P < 0.001) as measured on Ga-68 PSMA PET/CT compared to those lesions that were not detected. All lymph nodes greater than 10mm in size were detected while only 28% of nodes less than 10mm were detected by Tc-99m HYNIC PSMA SPECT/CT. In a univariate analysis, Lymph node size (P = 0.033) and the SUVmax of all lesions (P = 0.007) were significant predictors of lesion detection on Tc-99m HYNIC PSMA SPECT/CT. Conclusion: Tc-99m HYNIC PSMA may be a useful in imaging of prostate cancer although with a lower sensitivity for lesion detection compared to Ga-68 PSMA PET/CT. Its use is recommended when Ga-68 PSMA is not readily available, in planning radio-guided surgery or the patient is being considered for radio-ligand therapy with Lu-177 PSMA. It performs poorly in detecting small-sized lesions hence its use is not recommended in patients with small volume disease.
引用
收藏
页码:1205 / 1212
页数:8
相关论文
共 26 条
[1]   PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions [J].
Afshar-Oromieh, A. ;
Malcher, A. ;
Eder, M. ;
Eisenhut, M. ;
Linhart, H. G. ;
Hadaschik, B. A. ;
Holland-Letz, T. ;
Giesel, F. L. ;
Kratochwil, C. ;
Haufe, S. ;
Haberkorn, U. ;
Zechmann, C. M. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 (04) :486-495
[2]   Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].
Afshar-Oromieh, Ali ;
Zechmann, Christian M. ;
Malcher, Anna ;
Eder, Matthias ;
Eisenhut, Michael ;
Linhart, Heinz G. ;
Holland-Letz, Tim ;
Hadaschik, Boris A. ;
Giesel, Frederik L. ;
Debus, Juergen ;
Haberkorn, Uwe .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20
[3]  
[Anonymous], 2016, CNM
[4]  
[Anonymous], J CLIN ONCOL
[5]   Prostate Cancer in South Africa: Pathology Based National Cancer Registry Data (1986-2006) and Mortality Rates (1997-2009) [J].
Babb, Chantal ;
Urban, Margaret ;
Kielkowski, Danuta ;
Kellett, Patricia .
PROSTATE CANCER, 2014, 2014
[6]   What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer [J].
Ballas, Leslie K. ;
Abreu, Andre Luis de Castro ;
Quinn, David I. .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 :6S-12S
[7]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[8]   Prostate-Specific Membrane Antigen-Based Imaging in Prostate Cancer: Impact on Clinical Decision Making Process [J].
Demirkol, Mehmet Onur ;
Acar, Omer ;
Ucar, Burcu ;
Ramazanoglu, Sultan Rana ;
Saglican, Yesim ;
Esen, Tarik .
PROSTATE, 2015, 75 (07) :748-757
[9]   Development of a Single Vial Kit Solution for Radiolabeling of 68Ga-DKFZ-PSMA-11 and Its Performance in Prostate Cancer Patients [J].
Ebenhan, Thomas ;
Vorster, Mariza ;
Marjanovic-Painter, Biljana ;
Wagener, Judith ;
Suthiram, Janine ;
Modiselle, Moshe ;
Mokaleng, Brenda ;
Zeevaart, Jan Rijn ;
Sathekge, Mike .
MOLECULES, 2015, 20 (08) :14860-14878
[10]  
Even-Sapir E, 2006, J NUCL MED, V47, P287